
Loading, please wait...

Loading, please wait...

Heart failure continues to be a global healthcare challenge, particularly within aging populations and resource-limited regions like India. To address this, researchers have developed a novel colorimetric sensing technique called CQmiR for early heart failure diagnosis. By targeting heart failure-specific microRNAs (miRNAs) in whole blood, this technology offers a rapid and quantitative solution for clinical assessment. MicroRNAs serve as highly stable and specific biomarkers, reflecting the underlying pathological changes in cardiac tissue before symptoms become severe.
The CQmiR system utilizes a specialized nanoprobe patch coated with RNA-binding proteins. Furthermore, this patch efficiently extracts miRNAs directly from complex biological samples such as whole blood. After extraction, the system employs loop-mediated isothermal amplification to amplify the genetic material on a chip. Consequently, clinicians can achieve sub-femtomolar sensitivity and single-nucleotide specificity within just two hours. This process does not require any sophisticated lab equipment, making it ideal for point-of-care use.
In a recent rodent model study, this approach successfully detected molecular risks associated with heart failure before the onset of symptoms. Specifically, researchers highlighted the critical roles of miR-652-3p and miR-30e-5p as primary indicators. Because the test is low-cost and highly efficient, it holds significant potential for large-scale screening. Therefore, this innovation could transform how we manage cardiovascular health by moving diagnostics closer to the patient’s home.
MicroRNAs are small non-coding RNA molecules that regulate gene expression. In heart failure, specific miRNAs like miR-652-3p are released into the blood, acting as early warning signals of cardiac stress before physical symptoms appear.
Yes, the CQmiR assay is designed for non-clinical environments. Since it uses a colorimetric sensing technique and does not require expensive laboratory hardware, it is suitable for community health centers or primary clinics.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Wan Y et al. Colorimetric Sensing of MicroRNAs in Whole Blood for Early Diagnosis of Heart Failure. ACS Sens. 2026 Feb 25. doi: 10.1021/acssensors.5c03201. PMID: 41739548.
HalvaeiKhanekahdani P, Wu Y, Ta HT. miRNAs in cardiovascular disease and an update on emerging trend in electrochemical biosensors for miRNA detection. Crit Rev Biotechnol. 2025 Nov 23:1-28. doi: 10.1080/07388551.2025.2584689. PMID: 41276298.
Technology Networks. microRNA Biomarkers Improve Heart Failure Diagnosis in Women. 2025 Oct 31.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers have developed CQmiR, a low-cost, portable colorimetric sensing patch that detects heart failure biomarkers in blood within two hours....
7 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today